Joshua Disbrow Net Worth

The estimated Net Worth of Joshua R. Disbrow is at least $1.22 Million dollars as of 29 July 2024. Mr. Disbrow owns over 7,000 units of Aytu BioPharma Inc stock worth over $180,720 and over the last 12 years he sold AYTU stock worth over $0. In addition, he makes $1,043,700 as Chairman of the Board and Chief Executive Officer at Aytu BioPharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Disbrow AYTU stock SEC Form 4 insiders trading

Joshua has made over 9 trades of the Aytu BioPharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of AYTU stock worth $58,240 on 29 July 2024.

The largest trade he's ever made was buying 250,000 units of Aytu BioPharma Inc stock on 6 May 2016 worth over $100,000. On average, Joshua trades about 40,431 units every 107 days since 2012. As of 29 July 2024 he still owns at least 72,000 units of Aytu BioPharma Inc stock.

You can see the complete history of Mr. Disbrow stock trades at the bottom of the page.

Joshua Disbrow biography

Joshua R. Disbrow serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Disbrow has been employed by us since April 16, 2015 and a member of our Board of Directors since January 2016. Prior to the closing of the merger with Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioScience, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. (“Ampio”) from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals LLC (“Arbor”), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company’s second full-time employee. Mr. Disbrow led the company’s commercial efforts from inception to the company’s acquisition in 2010 and growth to over $127 million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University.

What is the salary of Joshua Disbrow?

As the Chairman of the Board and Chief Executive Officer of Aytu BioPharma Inc, the total compensation of Joshua Disbrow at Aytu BioPharma Inc is $1,043,700. There are no executives at Aytu BioPharma Inc getting paid more.

How old is Joshua Disbrow?

Joshua Disbrow is 44, he's been the Chairman of the Board and Chief Executive Officer of Aytu BioPharma Inc since 2016. There are 9 older and 1 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.

What's Joshua Disbrow's mailing address?

Joshua's mailing address filed with the SEC is 9655 MAROON CIRCLE, , ENGLEWOOD, CO, 80112.

Insiders trading at Aytu BioPharma Inc

Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery, and Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.

What does Aytu BioPharma Inc do?

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.

Complete history of Mr. Disbrow stock trades at Ampio Pharmaceuticals Inc, Aytu BioPharma Inc, and Zynex Inc

Aytu BioPharma Inc executives and stock owners

Aytu BioPharma Inc executives and other stock owners filed with the SEC include:

• Joshua Disbrow,
  Chairman of the Board, Chief Executive Officer
• Joshua R. Disbrow,
  Chairman & CEO
• Jarrett Disbrow,
  Chief Operating Officer
• David Green,
  Chief Financial Officer, Treasurer, Secretary
• Michael Macaluso,
  Independent Director
• John Donofrio,
  Independent Director
• Carl Dockery,
  Independent Director
• Gary Cantrell,
  Independent Director
• Ketan Mehta,
  Director
• James Carbonara,
  IR Contact Officer
• Steven Boyd,
  Director
• Matthew Phillips,
  Executive Vice President - Commercial Operations
• Russ McMahen,
  Sr. VP of R&D
• Topher Brooke,
  Exec. VP of Rare Disease Devel.
• Nate Massari,
  Exec. VP of Rare Disease Operations
• Greg Pyszczymuka,
  Chief Commercial Officer
• Jarrett T. Disbrow Ph.D.,
  Exec. VP of Corp. Operations
• Beth Hecht,
  Director
• Gerald W. Mc Laughlin,
  Director
• Inc. Cerecor,
  10% owner
• Capital Management, Llc Har...,
  
• Gregory A Gould,
  Chief Financial Officer
• Jonathan H Mc Grael,
  Vice President of Sales
• Pharmaceuticals, Inc. Ampio,
  10% owner
• Mark K Oki,
  Chief Financial Officer
• Greg Pyszczymuka,
  Chief Commercial Officer
• Christopher Brooke,
  Chief Operating Officer
• Abhinav Jain,
  
• Vivian H Liu,
  
• Richard I Eisenstadt,
  Chief Financial Officer